-

Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos

Medisca today announced that Founder and Chairman Antonio Dos Santos has returned to the role of Chief Executive Officer as the company enters its next chapter of growth.

MONTREAL--(BUSINESS WIRE)--For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company's long-term strategy, with a focus on expanding Medisca's global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day.

As Medisca enters its next chapter, we remain committed to raising the standard of pharmaceutical compounding and supporting healthcare professionals with the products, knowledge, and innovation they need to deliver better patient care.

Share

"When I founded Medisca, my vision was to raise the standard of pharmaceutical compounding by bringing pharmaceutical-grade quality to the industry and giving healthcare professionals access to the products, knowledge, and innovation they needed to deliver better patient care," said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. "That purpose continues to guide us. As we begin this next chapter, we'll keep investing in our people, our partnerships, and the innovation that will help shape the future of Medisca and the pharmaceutical compounding industry."

Working alongside Vice-Chair Maria Zaccardo and Medisca's C-Suite, Dos Santos will continue to guide the company's strategic direction as Medisca continues to expand globally and invest in its long-term growth.

“For over three decades, Medisca has grown by staying true to its purpose while continuing to evolve with the needs of healthcare professionals,” said Maria Zaccardo, Vice-Chair of Medisca. “As we look ahead, we remain focused on supporting our customers, investing in our people, and continuing to strengthen Medisca for the future.”

As part of this leadership transition, Sanjay Goorachurn has stepped down from his role as Chief Executive Officer. Medisca thanks Sanjay for his dedication and contributions to the organization and wishes him continued success.

As Medisca continues to grow globally, the company remains committed to empowering personalized wellness for all by expanding the products, technologies, education, and expertise that help healthcare professionals deliver better patient care around the world.

About Medisca

Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products completed by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.Medisca.com and follow us on LinkedIn, Facebook, and YouTube.

Contacts

Medisca Communications
communications@medisca.com
1-800-665-6334

Industry:

Medisca

Release Versions
English
Hashtags
#Medisca
#PersonalizedHealthcare
#PharmaceuticalCompounding
#personalizedmedicine

Contacts

Medisca Communications
communications@medisca.com
1-800-665-6334

More News From Medisca

Medisca and dsm–firmenich Partner to Expand Access to Pharmaceutical-Grade Vitamin APIs for U.S. Compounding Market

MONTREAL--(BUSINESS WIRE)--Medisca, a global leader in personalized pharmaceutical medicine, has entered into a strategic partnership with dsm–firmenich, a leading ingredient manufacturer serving regulated pharmaceutical markets worldwide. Through this partnership, Medisca will make a portfolio of pharmaceutical-grade vitamin active pharmaceutical ingredients (APIs) available to U.S. compounding professionals, expanding access to ingredients manufactured within European cGMP environments and su...

Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,600, 11,090,224, 11,096,864, 10,231,903, and 10,993,876. The confidential settlement resolves the pending litigation. “This settlement validates the investment Medisca has made over the past decade in the MAZ innovation and technology,” said Sanjay Goorachu...

Medisca Statement on Settlement With Department of Justice

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca Inc. has reached an agreement with the United States Department of Justice (DOJ) to resolve and terminate a civil investigation that began 9 years ago. The allegations made by the DOJ relate to the accuracy of the company’s disclosure of average wholesale prices (AWPs) for certain pharmaceutical ingredients from January 2012 to May 2015, and the reimbursement by the TRICARE program of pharmacies that purchased these ingredients at a price lower than t...
Back to Newsroom